Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Voriconazole may increase risk for squamous cell carcinoma in allogeneic HCT patients

09 Oct 2017

Use of voriconazole appears to increase the risk specifically for squamous cell carcinoma (SCC) in the allogeneic haematopoietic cell transplantation (HCT) population, according to a recent study.

To examine the effect of voriconazole on the risk for nonmelanoma skin cancer (NMSC), including SCC and basal cell carcinoma, researchers conducted a retrospective cohort study involving 1,220 individuals who had undergone allogeneic HCT and 1,418 who had undergone autologous HCT. Voriconazole exposure and other known risk factors for NMSC were included in multivariate analysis.

Multivariate analyses revealed that using voriconazole elevated the risk for NMSC (hazard ratio [HR], 1.82; 95 percent CI, 1.13 to 2.91) among patients who had undergone allogeneic HCT, particularly for SCC (HR, 2.25; 1.30 to 3.89). In patients who had undergone autologous HCT, using voriconazole did not contribute to an increased risk for NMSC.

In an earlier study, Wojenski and colleagues identified cumulative days of voriconazole use as a predictor of SCC development following allogeneic HCT. This information, according to them, may help guide appropriate antifungal use in this patient population. [Transpl Infect Dis 2015;17:250-8]

Meanwhile, a study by Boast and colleagues on voriconazole dosing and therapeutic drug monitoring (TDM) in children found a significant intra- and interindividual variability in voriconazole concentrations in children, particularly those <6 years of age, which warranted repeated TDM throughout treatment. The authors also recommended standardized guidelines for TDM and dose adjustment in children. [J Antimicrob Chemother 2016;71:2031-6]

The current study is limited by its retrospective design, according to researchers, adding that voriconazole has previously been tied to an increased risk for cutaneous SCC in solid organ transplant recipients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.